title: Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
authors.affiliation: Breast Cancer Medicine Service, Department of medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. trainat@mskcc.org
authors.forename: Tiffany A
authors.initials: TA
authors.lastname: Traina
authors.forename: Larry
authors.initials: L
authors.lastname: Norton
authors.forename: Karen
authors.initials: K
authors.lastname: Drucker
authors.forename: Buvanesh
authors.initials: B
authors.lastname: Singh
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009300:Nasal Septum / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology*; D009668:Nose Diseases / Q000139:chemically induced* / Q000175:diagnosis; D017239:Paclitaxel / Q000008:administration & dosage; D011859:Radiography; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel